Tag: Doctor

  • The Benzo Balance: Short-Term Help, Long-Term Plan

    The Benzo Balance: Short-Term Help, Long-Term Plan

    1. Clarity and upfront expectations reduce long-term problems

    “I’m prescribing this for 4–6 weeks. After that, we taper.”
    We give the patient a clear framework and prevent long-term dependency from becoming the default trajectory. It builds trust while still honoring clinical caution. Patients usually appreciate this transparency.

    2. Dose low. Time-limit strictly

    This really is the heart of rational benzo use. When used short-term for acute anxiety, panic, alcohol withdrawal, catatonia, etc., they can be valuable. But once we drift into long-term, open-ended prescribing, the benefits decline and risks (dependence, cognitive impairment, falls, tolerance) mount.

    3. Cold-turkey tapers can be dangerous

    “Some well-meaning physician decides to pull someone off benzodiazepines in 2 weeks…”
    And suddenly the patient is in crisis — not because the drug was inherently evil, but because the withdrawal was mishandled. Abrupt tapers, especially in someone on high doses or for years, can trigger rebound anxiety, insomnia, panic, even seizures or suicidality.

    4. We need to hold both truths at once

    • Benzos are not long-term solutions for anxiety.
    • But abrupt discontinuation without a tailored plan is often worse than the original problem.

    It’s not a complex principle, but it takes nuanced execution. You’re advocating for that middle path: compassionate, firm, individualized.

  • Dexmedetomidine for Acute Agitation in Bipolar and Schizophrenia: Worth the Hype?

    I recently received a great question about the use of dexmedetomidine for acute agitation. With its recent FDA approval for agitation associated with bipolar disorder and schizophrenia, it’s only natural to wonder: is this the new go-to treatment, or just another overhyped medication?

    Let’s start with the obvious. New medications almost always come with a hefty price tag. That cost is only justifiable if they outperform existing options in either efficacy or safety—and in this case, dexmedetomidine falls short on both fronts.

    Current data suggest it does not provide superior outcomes when compared to existing, well-established medications like lorazepam, haloperidol, or olanzapine. And it brings along its own baggage: bradycardia, hypotension, and sedation-related complications that can be clinically significant, especially in medically complex patients.

    When you combine the high cost with a safety profile that raises some red flags—and no clear advantage in efficacy—it becomes hard to justify widespread use.

    For now, I’d place dexmedetomidine in the “hype” category. We already have effective, affordable options with strong track records in managing acute agitation. Until further data prove otherwise, there’s little reason to switch.

  • Understanding Social Anxiety Disorder: Key Insights and Treatments

    Understanding Social Anxiety Disorder: Key Insights and Treatments

    What if your biggest fear was simply being seen?
    For millions living with Social Anxiety Disorder (SAD), everyday interactions—like answering a question in class or speaking up at work—can feel terrifying. Despite being one of the most prevalent and impairing anxiety conditions, SAD remains widely under-recognized.

    📊 Up to 8.4% of people meet criteria for SAD in a given year, yet only 20–40% recover after 20 years without treatment (Ruscio et al., 2008). Median age of onset? Just 13 years old.

    👤 Case Vignette: When Fear Takes Over

    At 15, “Jenna” stopped raising her hand in class—not because she didn’t know the answers, but because she was terrified of being laughed at. By college, she avoided presentations, skipped networking events, and turned down internships. Her friends thought she was shy. One professor suggested depression. But underneath was a paralyzing fear of judgment: classic Social Anxiety Disorder.

    🤝 What Is Social Anxiety Disorder?

    SAD is more than introversion or shyness. It’s a persistent, intense fear of being judged, embarrassed, or negatively evaluated in social or performance situations. This fear leads to avoidance behaviors that impair social, academic, and occupational functioning.

    ⚠️ Why Is It So Often Missed?

    SAD is frequently overshadowed by overlapping symptoms seen in:

    • Major Depressive Disorder (social withdrawal, low self-esteem)
    • Generalized Anxiety Disorder (excessive worry)
    • Avoidant Personality Disorder (longstanding social inhibition)
    • Body Dysmorphic Disorder (fear of negative evaluation tied to appearance)

    Because of this diagnostic overlap, many individuals go undiagnosed—or misdiagnosed—for years.

    🧠 Clinical Considerations

    1. SAD Is Not “Just Shyness”

    Shyness is a personality trait; SAD is a clinical condition. The difference lies in impairment: SAD interferes with daily life, relationships, academic goals, and career opportunities.

    2. Early Onset, Long Course

    Most individuals report symptoms starting in early adolescence. Without intervention, SAD often persists into adulthood and increases the risk of depressionsubstance use, and functional disability.

    3. Functional Impairment Is Significant

    SAD can lead to:

    • Academic underachievement
    • Avoidance of job interviews or public speaking
    • Social isolation
    • Delayed life milestones (e.g., dating, career advancement)

    4. Evidence-Based Treatments Exist

    🧠 Cognitive Behavioral Therapy (CBT):

    • Gold-standard psychotherapy
    • Targets negative thought patterns and avoidance behaviors
    • Often includes exposure exercises to feared situations
    • Group CBT is especially effective for SAD

    💊 Pharmacologic Options:

    • First-line: SSRIs (e.g., sertraline, paroxetine)
    • SNRIs: Like venlafaxine, also effective
    • Beta-blockers: May help with performance-only SAD (e.g., public speaking)
    • BenzodiazepinesNot recommended due to dependence risks and avoidance reinforcement

    🔄 Combined Therapy

    Some individuals benefit most from CBT + medication, particularly those with moderate-to-severe or treatment-resistant symptoms.

    📣 Call to Action

    Too many individuals live in silence with Social Anxiety Disorder. If you or someone you know avoids social situations due to fear of judgment, don’t ignore it. SAD is real. It’s common. And—most importantly—it’s treatable.

    👉 Talk to a mental health professional
    👉 Share this post to raise awareness
    👉 Start the conversation

  • 📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

    📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

    📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

    According to newly released CDC data, the U.S. experienced a nearly 27% decline in overdose deaths last year — the first major drop in over five years. While the crisis is far from over, this marks a critical turning point and a reason for cautious optimism.

    Key contributors to this progress include:

    ✅ Expansion of harm reduction strategies

    ✅ Increased access to naloxone and medications for opioid use disorder

    ✅ Shifts in drug supply dynamics and targeted public health interventions

    As someone on the front lines caring for patients every day, I’ve witnessed firsthand the devastating toll of opioid addiction. I’ve lost patients to this crisis — and I’ve also seen close friends and family fight their way back from the brink. Their recovery wouldn’t have been possible without access to critical resources, especially life-saving medications and sustained support.

    This progress didn’t happen by chance — it’s the result of continued investment in prevention, treatment, and recovery. We cannot afford to lose momentum now. If anything, this is the moment to double down.

    Let’s keep the pressure on. Reach out to your representatives. Push for increased funding. Our collective commitment has brought us this far — now let’s go even further. Lives depend on it.

    Let’s build on this progress with compassion, science, and unwavering commitment.

  • Avoid Tianeptine: FDA Alerts Consumers to Risks

    Avoid Tianeptine: FDA Alerts Consumers to Risks

    The U.S. Food and Drug Administration (FDA) has issued a critical health warning about the growing availability of tianeptine, a dangerous, unapproved substance being sold as a dietary supplement under names like Zaza, Tianna Red, Pegasus, and others.

    Commonly referred to as “gas station heroin”, tianeptine mimics opioid-like effects and is being sold in convenience stores, gas stations, smoke shops, and online—posing serious health risks to the public.

    ⚠️ Why This Matters:

    Tianeptine is not approved for any medical use in the U.S. Despite this, it is widely marketed for supposed benefits like mood enhancement, anxiety relief, or cognitive boost. These claims are not supported by clinical evidence, and the risks are significant.

    🩺 Serious Health Risks Associated With Tianeptine:

    ⚠️ Death, particularly when combined with alcohol or other substances

    ⚠️ Respiratory depression (slow or stopped breathing)

    ⚠️ Seizures

    ⚠️ Loss of consciousness

    ⚠️ Confusion and agitation

    ⚠️ Opioid-like withdrawal symptoms

    🛑 What You Can Do:

    Report adverse reactions to the FDA via MedWatch: https://www.fda.gov/medwatch

    Avoid any products labeled as containing tianeptine.

    Do not trust unregulated supplements marketed for mental clarity or energy.

    📌 Quick Summary:

    • Tianeptine = dangerous, unapproved opioid-like drug
    • Sold as a supplement under names like Zaza or Tianna Red
    • Linked to seizures, coma, and death
    • Avoid these products and warn others
    • Report side effects to the FDA MedWatch Program
  • The Importance of Distinguishing Suicidal Behaviors

    The Importance of Distinguishing Suicidal Behaviors

    This is the subject of a recent discussion I had with a colleague regarding the differences between a suicide attempt and a suicide gesture. Though these terms are sometimes used interchangeably in casual conversation or even in clinical documentation, they carry fundamentally different meanings—both in terms of patient risk and in how we, as clinicians, should respond.

    Our conversation emerged from a case involving a patient with borderline personality disorder who presented to the emergency department after ingesting a small quantity of over-the-counter medication. The intent was unclear. Was this a serious attempt to end her life? Or was it a gesture—an act of desperation without the intention to die, but rather to communicate emotional distress?

    The question is not academic. Our interpretation of the event determines our risk formulation, our documentation, our treatment planning, and even how we communicate with the patient and their support system. Yet, it is precisely in these gray areas that clinicians often struggle, and where outdated or stigmatizing language can do real harm.

    Defining the Terms: Clinical and Functional Differences

    suicide attempt refers to an act of self-harm with at least some intent to die. The degree of lethality may vary, but what distinguishes an attempt is that the individual believed the act could result in death and engaged in it with that goal in mind—even if ambivalence was present. The National Institute of Mental Health (NIMH) and the Columbia-Suicide Severity Rating Scale (C-SSRS) define this with some specificity: any potentially self-injurious behavior with non-zerointent to die, regardless of outcome.

    In contrast, a suicidal gesture is a behavior that mimics suicidal behavior or appears life-threatening but is typically not intended to be fatal. The function is often communicative or affect-regulating rather than aimed at death. Classic examples include superficial wrist-cutting, ingesting a sub-lethal dose of medication, or tying a noose but not tightening it. These acts often occur in interpersonal contexts and can be seen as efforts to signal pain, elicit help, or assert control in the face of perceived abandonment.

    Why the Distinction Matters

    It might be tempting to dismiss suicidal gestures as “attention-seeking” or “manipulative,” but this framing is both clinically dangerous and ethically fraught. Individuals who engage in gestures often experience intense psychological suffering, and repeated gestures are a well-established risk factor for future suicide attempts and completed suicide.

    From a risk assessment standpoint, gestures should be taken seriously, especially when they become part of a pattern. While the intent to die may not be present in a given gesture, intent can shift quickly, particularly in individuals with mood disorders, personality pathology, or under the influence of substances.

    From a treatment perspective, understanding the function of the behavior—whether it is to relieve affective tension, to communicate distress, or to punish oneself—is crucial to tailoring interventions. For instance, dialectical behavior therapy (DBT) explicitly targets self-harm and suicidal gestures as part of its hierarchy of treatment priorities, recognizing the urgency and potential danger of these behaviors even when lethality is low.

    Conclusion: Clarify, Don’t Categorize

    Ultimately, the conversation with my colleague reminded me that the real clinical challenge is not to label a behavior as a suicide attempt or a gesture, but to understand its meaning in the life of the patient. Both require empathy, structure, and a willingness to engage with complexity. Whether a patient wants to die or wants their suffering to be seen and acknowledged, both deserve serious clinical attention.

    By sharpening our definitions and approaching these behaviors with nuance, we can better serve patients in crisis and avoid the pitfalls of assumptions—especially in emotionally charged clinical environments like emergency rooms, inpatient units, or high-acuity outpatient settings.

  • EMA Warns of Suicidal Ideation from Finasteride

    EMA Warns of Suicidal Ideation from Finasteride

    In a significant update to its safety guidance, the European Medicines Agency (EMA) has officially recognized suicidal ideation as a potential side effect of finasteride. The EMA is urging healthcare professionals to advise patients to stop treatment and seek medical help if they experience depressed mood, depression, or suicidal thoughts while taking the drug.

    This decision follows a growing number of reports linking finasteride, particularly in younger men using it for androgenic alopecia (male pattern baldness), to neuropsychiatric side effects. While previous warnings have addressed sexual dysfunction, this marks a critical shift in regulatory focus to mental health.

    💊 What Is Finasteride?

    Finasteride is a 5α-reductase inhibitor used to treat:

    • Benign prostatic hyperplasia (BPH) in a 5 mg daily dose (Proscar)
    • Male pattern baldness (androgenic alopecia) in a 1 mg daily dose (Propecia)

    It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT)—a potent androgen implicated in hair loss and prostate growth.

    ⚠️ The EMA’s Updated Warning

    The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed post-marketing surveillance data and published literature and concluded that:

    “There is sufficient evidence to support a causal relationship between finasteride and the risk of suicidal ideation.”

    Key recommendations:

    • Suicidal ideation will be added to the drug’s product information as a potential adverse effect.
    • Healthcare professionals should proactively inform patients about this risk.
    • Patients should be advised to discontinue treatment immediately and seek medical advice if they experience changes in mood or mental health.

    🧠 Possible Mechanisms Behind Finasteride’s Psychiatric Effects

    The exact mechanisms linking finasteride to depression and suicidality remain unclear, but several biological hypotheseshave been proposed:

    1. Neurosteroid Depletion

    Finasteride inhibits 5α-reductase, which not only converts testosterone to DHT but also helps produce neurosteroids like allopregnanolone and tetrahydrodeoxycorticosterone (THDOC).

    • These neurosteroids have potent GABAergic activity, contributing to anxiolytic and antidepressant effects.
    • Inhibition leads to decreased GABA-A receptor modulation, potentially increasing anxiety, depression, and suicidal thoughts.

    2. Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

    Altered steroid metabolism may dysregulate the HPA axis, increasing cortisol levels, a well-known biomarker of depression and suicidal behavior.

    3. Persistent Epigenetic Changes

    Some animal and human data suggest that finasteride may induce long-lasting changes in gene expression related to stress response and mood regulation, even after discontinuation—supporting the idea of post-finasteride syndrome (PFS).

    4. Neuroinflammation

    Reduced neurosteroids may increase neuroinflammatory signaling, a growing area of interest in the neurobiology of depression and suicidality.

    🧾 Final Thoughts

    The EMA’s announcement is a sobering reminder that drugs affecting hormonal pathways can have wide-reaching systemic effects, including on the brain. With better awareness, screening, and patient education, we can minimize harm and support individuals who may be at risk.

  • Substance-Induced Psychosis vs. Primary Psychosis: Treatment, Prognosis, and the Cannabis Connection

    Substance-Induced Psychosis vs. Primary Psychosis: Treatment, Prognosis, and the Cannabis Connection

    Psychosis can emerge from a range of causes, but distinguishing between substance-induced psychosis (SIP) and primary psychotic disorders like schizophrenia is critical for effective treatment and prognosis. While the clinical presentation often overlaps—hallucinations, delusions, disorganized thinking—the underlying etiology, treatment approach, and long-term outcomes can diverge significantly.

    Defining the Two

    Substance-Induced Psychosis (SIP) occurs when symptoms of psychosis are directly caused by intoxication with or withdrawal from substances such as cannabis, amphetamines, alcohol, hallucinogens, or synthetic cannabinoids (e.g., spice or K2). The psychosis typically emerges during or shortly after substance use and resolves with abstinence.

    Primary Psychosis, on the other hand, refers to psychotic disorders that are not directly attributable to substances or medical conditions. This includes schizophreniaschizoaffective disorder, and brief psychotic disorder, among others.

    Treatment: Overlapping Tools, Different Emphasis

    1. Acute Management
    Both SIP and primary psychosis are often treated with antipsychotic medications during acute episodes. The initial goals are the same: reduce agitation, manage delusions or hallucinations, and ensure safety.

    • Commonly used antipsychotics include risperidone, olanzapine, haloperidol, and quetiapine. In SIP, short-term use is typically sufficient.
    • In cases involving severe agitation or aggression, benzodiazepines (like lorazepam) may be used adjunctively, especially if stimulant intoxication is suspected.

    2. Long-Term Strategy

    • SIP: After stabilization, the primary strategy is abstinence from the offending substance and psychosocial support (e.g., CBT, motivational interviewing, relapse prevention).
    • Primary psychosis: Typically requires ongoing antipsychotic treatment, often for life. Psychosocial interventions, supported employment, and cognitive remediation are also central to recovery.

    Conversion to Schizophrenia: What’s the Risk?

    One of the key concerns with SIP is whether the episode is a harbinger of an underlying primary psychotic disorder.

    • Approximately 20–50% of individuals with substance-induced psychosis later develop a primary psychotic disorder, such as schizophrenia.
    • Amphetamine- and cannabis-induced psychosis carry the highest risk of conversion, particularly when psychosis occurs in adolescence or early adulthood.
    • meta-analysis by Niemi-Pynttäri et al. (2013) found that 46% of people with SIP later developed schizophrenia-spectrum disorders over a follow-up of 8 years.

    Predictors of conversion include:

    • Younger age at first psychotic episode
    • Family history of psychotic illness
    • Persistent psychotic symptoms after substance clearance
    • Poor premorbid functioning

    Do Antipsychotics Work in SIP?

    Antipsychotics reduce acute psychotic symptoms in SIP, but their long-term utility is less clear.

    • Studies show rapid resolution of psychosis within days to weeks in most SIP cases when abstinence is achieved.
    • Long-term antipsychotic treatment does not reduce the conversion rate to schizophrenia in confirmed SIP, suggesting their role should be time-limited unless ongoing symptoms or risk factors emerge.
    • A 2020 review in Psychological Medicine emphasized that monitoring over the 6–12 months post-episode is essential for risk stratification and avoiding premature chronic medication exposure.

    Cannabis: A Powerful Catalyst

    Cannabis has become the most studied and most controversial substance linked to psychosis. Here’s what the evidence says:

    • Daily cannabis users are 3–5 times more likely to develop a psychotic disorder compared to non-users, especially with high-THC strains (≥10% THC).
    • A 2019 Lancet Psychiatry study by Di Forti et al. showed that strong cannabis use accounts for 12% of new psychosis cases in Amsterdam, and 30% in London.
    • Adolescents who use cannabis, particularly those with a family history of psychosis, are at dramatically increased risk.

    Mechanistically, THC may dysregulate the dopamine system in vulnerable brains, tipping the balance toward psychosis. Cannabidiol (CBD), in contrast, may be protective, but commercial cannabis typically contains very little CBD.

    Final Thought: Clinicians must balance vigilance and restraint—treating psychosis aggressively when needed but also avoiding unnecessary chronic antipsychotic exposure in what may be a reversible, substance-driven episode.

  • ARISE Study Phase 3 Results: Understanding Xanomeline’s Setback

    ARISE Study Phase 3 Results: Understanding Xanomeline’s Setback

    What Was the ARISE Study?

    The ARISE trial was a Phase 3 clinical study evaluating Cobenfy — a combination of xanomeline (a muscarinic receptor agonist) and trospium chloride (a peripheral anticholinergic) — as an adjunctive treatment for adults with schizophrenia who continued to experience symptoms despite taking an atypical antipsychotic.

    What Is a Primary Endpoint, and Why Does It Matter?

    In clinical trials, the primary endpoint is the most important outcome researchers are trying to affect — it’s how a drug’s success or failure is officially judged.
    In ARISE, the primary endpoint measured the change in symptom severity compared to placebo using a standardized scale for schizophrenia. Meeting this endpoint would have demonstrated clear, statistically significant symptom improvement attributable to Cobenfy.

    The Outcome: No Statistically Significant Benefit

    According to topline results, Cobenfy did not show a statistically significant improvement compared to placebo when added to atypical antipsychotics. This means the observed difference could have been due to chance and did not meet the pre-set threshold for success.

    However, Cobenfy did show a numerical improvement — the group receiving the drug combination performed betterthan placebo in symptom reduction, just not to a statistically convincing degree.

    Could Anticholinergic Effects Be to Blame?

    One possible explanation for this outcome lies in the mechanism of action of both Cobenfy and many commonly used atypical antipsychotics.

    • Xanomeline is designed to activate muscarinic receptors in the brain (specifically M1 and M4), which may help regulate dopamine and reduce psychosis.
    • But many atypical antipsychotics — like olanzapine, clozapine, and quetiapine — also have anticholinergic properties, meaning they block these same receptors.

    This sets up a pharmacological tug-of-war: Cobenfy tries to stimulate muscarinic activity, while the background antipsychotic may be dampening it. This conflict could blunt the therapeutic signal, explaining why the benefit didn’t reach statistical significance.

    What This Means for the Future

    The failure to meet the primary endpoint is a setback, but not the end of the road. The numerical improvements suggest a potential signal, and with refined trial design — perhaps using background medications with lower anticholinergic load — future studies may better reveal Cobenfy’s potential.

    Additionally, this trial underscores the importance of considering mechanism compatibility in combination therapies. It’s not just about adding drugs — it’s about how they interact at the receptor level.

    Conclusion

    While the ARISE study didn’t deliver the result many hoped for, it raised critical questions that will shape future research. A deeper understanding of anticholinergic burden, drug synergy, and precision pharmacology is essential as we continue the search for more effective treatments for schizophrenia.

  • Adult ADHD: Current Trends and Emerging Research (2025 Update)

    Adult ADHD: Current Trends and Emerging Research (2025 Update)

    Attention-deficit/hyperactivity disorder (ADHD) has traditionally been seen as a childhood condition — but in recent years, there has been an explosion of interest in ADHD among adults. As awareness grows, so does research. New studies are reshaping how we diagnose, treat, and understand ADHD in the adult population.

    1. 🔥 Rising Rates of Adult ADHD Diagnosis

    Recent studies show that adult ADHD diagnoses have sharply increased over the past decade. According to a 2023 analysis published in JAMA Psychiatry, the diagnosis rate for adults aged 18–45 rose by more than 80% between 2011 and 2022.

    Why the surge?

    • Greater public awareness
    • Better screening tools for adults
    • A cultural shift toward recognizing executive dysfunction in adulthood

    However, there are concerns that overdiagnosis is also happening, particularly when ADHD is diagnosed after brief evaluations without thorough history-taking.

    2. 🧠 Expanded Understanding of Adult ADHD Symptoms

    The symptom profile in adults differs significantly from children. While hyperactivity often fades, issues like emotional dysregulationdisorganization, and executive dysfunction persist.

    Recent research emphasizes that adult ADHD often presents as:

    • Chronic procrastination
    • Low frustration tolerance
    • Difficulty managing responsibilities (work, home, finances)
    • Persistent inner restlessness

    A 2024 review in The American Journal of Psychiatry noted that emotional impulsivity may actually be a core symptomin adults, not just a secondary feature.

    3. 💊 Treatment Shifts: Caution Around Stimulants

    While stimulant medications (like amphetamines and methylphenidate) remain the gold standard, new studies highlight the importance of careful prescribing, especially in adults with:

    • Comorbid substance use disorders
    • Cardiovascular risk factors
    • Poor diagnostic workups

    Non-stimulant treatments are gaining ground:

    • Atomoxetine (Strattera) remains a mainstay.
    • Viloxazine (Qelbree) was approved for adult ADHD in 2024 and shows promise with lower abuse potential.
    • Bupropion (Wellbutrin) continues to be an important off-label option, especially when depression coexists with ADHD.

    According to a 2024 meta-analysis in Lancet Psychiatrynon-stimulants now account for about 30% of new ADHD prescriptions in adults — a significant jump compared to previous years.

    4. 🧬 Precision Psychiatry and Biomarkers on the Horizon

    Emerging studies are exploring neuroimaging and genetic markers to better understand adult ADHD subtypes.

    • A 2023 study using fMRI found distinct prefrontal cortex dysfunction patterns in adults with ADHD compared to controls.
    • Genetic research continues to implicate genes related to dopamine transmission and synaptic plasticity.

    Although these findings are not yet ready for clinical application, the future of ADHD diagnosis may involve biomarkers, moving beyond subjective questionnaires alone.

    5. 🌿 Lifestyle Interventions Are Getting More Attention

    There’s a growing body of evidence supporting complementary approaches:

    • Cognitive-behavioral therapy (CBT) for ADHD-specific skills
    • Exercise as a way to enhance executive function and mood
    • Mindfulness practices to improve emotional regulation

    A 2024 RCT published in Behavior Therapy showed that an 8-week mindfulness-based intervention led to significant improvements in attention and working memory in adults with ADHD — with effect sizes comparable to pharmacotherapy in some cases.

    Final Thoughts

    Adult ADHD is real, complex, and often misunderstood.
    The field is evolving rapidly, with a push toward better diagnosticssafer treatments, and a broader understanding of how ADHD affects life across the lifespan.

    As research continues to grow, clinicians are challenged not only to treat ADHD effectively but to do so thoughtfully — avoiding both underdiagnosis and overdiagnosis.

    Stay tuned — the future of ADHD care is just getting started.